Climb Bio, Inc. Files 8-K on Security Holder Vote

Ticker: CLYM · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1768446

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, filing

TL;DR

Climb Bio (formerly Eliem) had a shareholder vote on June 4th. 8-K filed.

AI Summary

Climb Bio, Inc. filed an 8-K on June 5, 2025, reporting on a matter submitted to a vote of its security holders on June 4, 2025. The company, formerly known as Eliem Therapeutics, Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing indicates a significant corporate action or decision requiring shareholder approval, which could impact the company's future direction and investor relations.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about financial distress, significant operational changes, or market-moving events.

Key Players & Entities

FAQ

What specific matter was submitted to a vote of Climb Bio, Inc.'s security holders on June 4, 2025?

The filing states that a 'Submission of Matters to a Vote of Security Holders' occurred on June 4, 2025, but does not specify the exact nature of the vote within this 8-K document.

When was Climb Bio, Inc. formerly known as Eliem Therapeutics, Inc.?

The company's name was changed from Eliem Therapeutics, Inc. on February 19, 2019.

What is Climb Bio, Inc.'s primary business sector?

Climb Bio, Inc. is classified under the Pharmaceutical Preparations sector, with SIC code 2834.

Where are Climb Bio, Inc.'s principal executive offices located?

The principal executive offices are located at 20 William Street, Suite 145, Wellesley Hills, Massachusetts 02481.

What is the SEC file number for Climb Bio, Inc.?

The SEC file number for Climb Bio, Inc. is 001-40708.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Climb Bio, Inc. (CLYM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing